Kura Oncology (NASDAQ:KURA) Shares Climb 4.2% – What’s Next?

Kura Oncology, Inc. (NASDAQ:KURA)’s stock price rose 4.2% on Wednesday. The stock traded as high as $10.97 and last traded at $10.97. Approximately 376,341 shares changed hands during trading, a decline of 77% from the average daily volume of 1,669,015 shares. The stock had previously closed at $10.53.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Wedbush boosted their price objective on Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a research report on Thursday, August 13th. Citizens Jmp reiterated a “market outperform” rating and set a $24.00 price target on shares of Kura Oncology in a research note on Monday, August 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a report on Friday, July 17th. UBS Group restated a “buy” rating on shares of Kura Oncology in a research note on Monday. Finally, JPMorgan Chase & Co. assumed coverage on shares of Kura Oncology in a research note on Thursday, October 1st. They issued an “overweight” rating and a $30.00 price objective for the company. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Kura Oncology has an average rating of “Moderate Buy” and a consensus target price of $25.69.

Kura Oncology Trading Down 1.4%

The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73. The company’s 50-day moving average is $11.32 and its 200-day moving average is $10.26. The firm has a market cap of $935.87 million, a price-to-earnings ratio of -3.12 and a beta of 0.47.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.The firm had revenue of $20.87 million during the quarter, compared to analysts’ expectations of $20.16 million. On average, research analysts predict that Kura Oncology, Inc. will post -3.25 earnings per share for the current year.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, SVP Thomas Doyle sold 4,607 shares of the firm’s stock in a transaction dated Monday, September 28th. The stock was sold at an average price of $10.50, for a total transaction of $48,373.50. Following the transaction, the senior vice president owned 142,428 shares in the company, valued at approximately $1,495,494. This trade represents a 3.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mollie Leoni sold 28,802 shares of the business’s stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $10.75, for a total value of $309,621.50. Following the transaction, the insider owned 141,095 shares of the company’s stock, valued at $1,516,771.25. The trade was a 16.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 153,881 shares of company stock valued at $1,708,183 over the last quarter. 7.60% of the stock is owned by corporate insiders.

Institutional Trading of Kura Oncology

A number of hedge funds have recently modified their holdings of KURA. BlackRock Inc. acquired a new position in Kura Oncology during the second quarter valued at approximately $115,286,000. Armistice Capital LLC boosted its position in shares of Kura Oncology by 5.7% during the fourth quarter. Armistice Capital LLC now owns 4,936,000 shares of the company’s stock worth $51,285,000 after purchasing an additional 264,000 shares in the last quarter. Bank of America Corp DE bought a new position in shares of Kura Oncology during the second quarter worth $12,735,000. Dimensional Fund Advisors LP grew its holdings in shares of Kura Oncology by 32.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock valued at $11,591,000 after buying an additional 348,127 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Kura Oncology in the 2nd quarter valued at $10,927,000.

Kura Oncology Company Profile

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company uses molecular and genomic insights to identify therapies designed to target specific biological drivers of tumor growth.

Kura’s lead program is ziftomenib, an oral menin inhibitor developed for genetically defined forms of acute myeloid leukemia, including disease associated with NPM1 mutations and KMT2A rearrangements. The company has also evaluated additional targeted oncology candidates, including therapies directed at the RAF-MEK-ERK signaling pathway.

Founded in 2014 and headquartered in San Diego, California, Kura has conducted clinical development activities through research collaborations and studies involving patients and institutions in the United States and other regions.